FDA Targets Executives With Powerful Misdemeanor Strategy
This article was originally published in The Tan Sheet
Executive Summary
Executives could face virtually unbeatable government criminal prosecutions and prison sentences more frequently if FDA follows recently announced enforcement plans, industry attorneys warn
You may also be interested in...
Park Doctrine Influence Could Wane In Upcoming Cases, Attorney Argues
As penalties increase under the responsible corporate officer doctrine, attorney Allison Burroughs says to expect increased scrutiny. A DoJ Consumer Protection Branch official says pharma execs will be held responsible because of the role the industry plays in consumers’ daily lives.
Park Doctrine Influence Could Wane In Upcoming Cases, Attorney Argues
As penalties increase under the responsible corporate officer doctrine, attorney Allison Burroughs says to expect increased scrutiny. A DoJ Consumer Protection Branch official says pharma execs will be held responsible because of the role the industry plays in consumers’ daily lives.
FDA Expects STD Claims Enforcement To Deter Future Violations
FDA will consider prosecuting executives of firms making unapproved sexually transmitted disease treatment claims for OTC drugs and nutritional products, the targets of its latest enforcement sweep.